Anavex Life Sciences Corp. Release: Sigma-1 Receptor Implicated In Cell Survival Of Rare Neurodegenerative Diseases - Expanding The Opportunity For Application Of ANAVEX PLUS In Rare Diseases
NEW YORK, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's.
Help employers find you! Check out all the jobs and post your resume.